Sagent Holding Co., the Schaumburg, Illinois, company that is developing generic injectable pharmaceuticals, has filed for a $100 million initial public offering just as a host of drug companies tap public capital markets, with many seeking to raise proceeds for research, according to the Wall Street Journal.
The company said only the funding would be used to fund "increasing working capital requirements" and other general purposes. It hopes to have 20 products launched by year's end.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Sagent originally raised $53 million in its first round in September 2007 and followed a year later with a $30 million extension. Vivo Ventures has lead each portion of this first-round fund raise.